Most patients diagnosed with breast cancer (BC) have hormone receptor (HR+)-positive disease.1 Endocrine therapy (ET) improves survival in HR + early-stage BC (EBC) and metastatic BC (MBC). The gene discussed is NR4A1; the disease is breast carcinoma.